Anavex Life Sciences Corp (AVXL)

[jimmy667]

Biogen sponsored the study. This is all Biogen centered. Both of Biogen’s drugs require infusion. At best for Biogen this is a “futility” study to start to build support for dropping these infusion MABs from further study before a possible crushing failure.
Is Biogen research becoming a liability rather than an asset so That Biogen is a Corp Raid target where Biogen is acquired for its profitable legacy drugs and the rest is sold off.
A failure of its stubborn Aducanumab program makes this more likely.